Following FDA approval of its abbreviated new drug application, or ANDA, Dr. Reddy's Laboratories (NYSE:RDY) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline's Lamictal.
Lamotrigine is an anticonvulsant used to treat epilepsy and bipolar disorders. The generic-drug maker said it launched the drug on June 25 and the extended-release tablets are available in dosages of 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg in 30-count bottles.
Dr. Reddy's Labs quotes IMS Health in noting the branded drug had domestic sales of approximately $300.5 million for the trailing 12-month period ending in April.
Fool contributor Rich Duprey and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.